Device Trial Radar · NCT06165510
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Aug 2, 2024
Primary completion
Nov 1, 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Barts & The London NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AtriCure, Inc.
- First posted
- Dec 11, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomised controlled clinical trial to assess efficacy of convergent ablation with the LARIAT procedure, as compared to standard endocardial catheter ablation in patients with long-standing persistent atrial fibrillation (AF).
Conditions
- Persistent Atrial Fibrillation
- Atrial Fibrillation, Persistent
- Atrium; Fibrillation
- Atrial Arrhythmia
Interventions
Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.Device
2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.
Standard Endocardial Catheter AblationProcedure
Standard percutaneous endocardial catheter ablation of atrial fibrillation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstrate trial feasibility with regards to recruitment rateTime frame: 24 months
- A composite of major adverse events (MAE) and complications occurring within 30 days post procedure will be measured.Time frame: 30 days post procedure
- Success or failure at 12 months of persistent AF patients to be free of: Atrial arrhythmia (classed as documentation of atrial fibrillation, atrial flutter or atrial tachycardia lasting for more than 30 seconds)Time frame: Measured from the end of a 3 month blanking period to 12 months post procedure
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St Bartholomew's Hospital
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.